12. Antifibrotic effects of Silymax Complex hard capsules on carbon tetrachloride-induced liver cirrhosis in mice
Main Article Content
Abstract
The antifibrotic effects of Silymax Complex hard capsules was evaluated in a Swiss mice model of CCl4 induced liver cirrhosis. At to gavage doses of 1.44 and 4.32 capsules/kg body weight for 19 weeks. Liver inflammation and fibrosis were evaluated by hepatosomatic index, HE staining, MDA and hydroxyproline assays, and biochemical tests. The results demonstrated that the administration of Silymax Complex did not significantly ameliorate the fibrosis and cirrhosis grading on histologically stained HE tissue sections, however, it was able to limit CCl4-induced liver injury by reducing serum AST, ALT and GGT levels; It also has the tendency to lower total bilirubin, improve serum albumin and total cholesterol levels, and decrease MDA concentrations in liver homogenate.
Article Details
Keywords
Silymax Complex, cirrhosis, carbon tetrachloride, mice
References
2. Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: A translational success story. Gut. 2015;64(5):830-841.
3. Said ES, Mohammed AH, Ali HM, Babiker AY, Alnughaymishi R, Althaqeel NZ, Ahmed AS. Evaluation of hepatoprotective effect of Nebivolol and sodium copper Chlorophyllin on CCl4-induced hepatotoxicity in mice. Eur Rev Med Pharmacol Sci. 2022;26(5):1717-1728.
4. Gillessen A, Schmidt HH. Silymarin as supportive treatment in liver diseases: A narrative review. Adv Ther. 2020;37(4):1279-1301.
5. Geethangili M, Ding ST. A review of the phytochemistry and pharmacology of phyllanthus urinaria L. Front Pharmacol. 2018;9:1109. doi: 10.3389/fphar.2018.01109.
6. Yang S, Yuan C. Schisandra chinensis: A comprehensive review on its phytochemicals and biological activities. Arabian Journal of Chemistry. 2021;14(9):103310. https://doi.org/ 10.1016/j.arabjc.2021.103310.
7. An S, Jang E, Lee JH. Preclinical evidence of curcuma longa and its noncurcuminoid constituents against Hepatobiliary diseases: A review. Evid Based Complement Alternat Med. 2020;2020:8761435. doi: 10.1155/2020/8 761435.
8. Arjmand A, Tsipouras MG, Tzallas AT, Forlano R, Manousou P, Giannakeas N. Quantification of liver fibrosis - A comparative study. Applied Sciences. 2020; 10(2):447. https://doi.org/10.3390/app10020447.
9. Scholten D, Trebicka J, Liedtke C, Weiskirchen R. The carbon tetrachloride model in mice. Lab Anim. 2015;49(1 Suppl):4-11.
10. Gabr SA, Alghadir AH, Sherif YE, Ghfar AA. Hydroxyproline as a biomarker in liver disease. In: Patel V, Preedy V, eds. Biomarkers in liver disease. Biomarkers in disease: Methods, discoveries and applications. Springer, Dordrecht; 2017:471-491. https://doi.org/10.1007/978-94-007-7675-3_26.
11. Guo Q, Zhang QQ, Chen JQ, Zhang W, Qiu HC, Zhang ZJ, Liu BM, Xu FG. Liver metabolomics study reveals protective function of Phyllanthus urinaria against CCl4-induced liver injury. Chin J Nat Med. 2017;15(7):525-533.
12. Xu JB, Gao GC, Yuan MJ, et al. Lignans from Schisandra chinensis ameliorate alcohol and CCl4-induced long-term liver injury and reduce hepatocellular degeneration via blocking ETBR. Journal of Ethnopharmacology. 2020;258:112813. https://doi.org/10.1016/j.jep. 2020.112813.